Minakem-flap
Minakem-flap

Find Clinical Drug Pipeline Developments & Deals by Vaccibody

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VB10.NEO

            Therapeutic Area: Oncology Product Name: VB10.NEO

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Genentech

            Deal Size: $715.0 million Upfront Cash: $200.0 million

            Deal Type: Collaboration November 06, 2020

            Details:

            Announced on October 1, 2020 the deal is now effective with the expiration of the HSR Act waiting period. Under the agreement, Genentech and Vaccibody will progress Vaccibody’s investigational product candidate, VB10.NEO, into clinical trials in the U.S. and in Europe.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VB10.NEO

            Therapeutic Area: Oncology Product Name: VB10.NEO

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Genentech

            Deal Size: $715.0 million Upfront Cash: $200.0 million

            Deal Type: Collaboration October 01, 2020

            Details:

            The agreements aims to develop and commercialize DNA-based individualized neoantigen vaccines for the treatment of cancers. Vaccibody will conduct development through the end of Phase 1b and Genentech will be responsible for development and commercialization thereafter.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bempegaldesleukin,VB10.NEO

            Therapeutic Area: Oncology Product Name: NKTR-214

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Recipient: Nektar Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 11, 2020

            Details:

            First patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's personalized neoantigen cancer vaccine.